泊马度胺杂质4 | 918314-45-1

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 泊马度胺杂质4
• 英文名称: 2H-Isoindole-2-butanoic acid, 4-amino-gamma-(aminocarbonyl)-1,3-dihydro-1,3-dioxo-
• 英文别名: 5-amino-4-(4-amino-1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid
• CAS: 918314-45-1
• 化学式: C₁₃H₁₃N₃O₅
• 分子量: 291.26
• InChiKey: JVYMXRZSOURPSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  144
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] METHODS FOR TREATING SOLID TUMORS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES<br/>[FR] MÉTHODES DE TRAITEMENT DE TUMEURS SOLIDES ET UTILISATION DE BIOMARQUEURS EN TANT QUE FACTEURS PRÉDICTIFS DE LA SENSIBILITÉ CLINIQUE À DES TRAITEMENTS IMMUNOMODULATEURS
  申请人：CELGENE CORPORATON

  公开号：WO2016060702A1

  公开（公告）日：2016-04-21

  A method of identifying a subject having a solid tumor who is likely to be responsive to a treatment compound, comprising: administering the treatment compound to a subject having the solid tumor; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject, and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker.

  一种识别可能对治疗化合物产生响应的固体肿瘤患者的方法，包括：向患有固体肿瘤的受试者施用治疗化合物；从受试者获取样本；确定来自受试者样本中生物标志物的水平，并且如果受试者样本中生物标志物的水平与生物标志物的参考水平相比发生变化，则诊断受试者可能对治疗化合物产生响应。
• [EN] COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON OTHER E3 UBIQUITIN LIGASES<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR INDUIRE DES MODIFICATIONS CONFORMATIONNELLES DANS CÉRÉBLON ET D'AUTRES UBIQUITINE LIGASES E3
  申请人：CELGENE CORP

  公开号：WO2015200795A1

  公开（公告）日：2015-12-30

  Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cerebloR, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.

  本文提供了基于对cerebloR、其底物和某些化合物或药剂相互作用阐明的组合物、治疗方法、筛选方法、计算方法和生物标志物。
• IMMUNOTHERAPY FOR HEMATOLOGICAL MALIGNANCIES
  申请人：Munshi Nikhil C.

  公开号：US20090068210A1

  公开（公告）日：2009-03-12

  Methods and compositions for treating, preventing and/or managing various hematological malignancies are disclosed. Specific methods and compositions relate to use of tumor cells engineered to express antigen presenting molecules which present antigens recognized by iNKT cells and eliciting antitumor immune response from iNKT cells using such tumor cells, optionally in combination with an immunomodulatory compound.

  本发明揭示了用于治疗、预防和/或管理各种血液恶性肿瘤的方法和组合物。具体的方法和组合物涉及使用经过工程改造以表达抗原呈递分子的肿瘤细胞，这些抗原呈递分子可以呈递被iNKT细胞识别的抗原，并使用这样的肿瘤细胞诱导iNKT细胞的抗肿瘤免疫反应，可选地与免疫调节化合物结合使用。
• Method of using and comopositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
  申请人：Zeldis Jerome B.

  公开号：US20090163548A1

  公开（公告）日：2009-06-25

  Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

  本发明涉及治疗、预防和/或管理骨髓增生性疾病的方法。具体方法包括单独或与第二活性剂联合给予免疫调节化合物或其药学上可接受的盐、溶剂化合物、水合物、立体异构体、笼合物或前药，和/或进行血液或细胞移植。特定的第二活性剂能够抑制造血干细胞的过度产生或改善骨髓增生性疾病的一个或多个症状。本发明还公开了适用于本发明方法的制药组合物、单剂量单位剂型和试剂盒。
• Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
  申请人：——

  公开号：US20040091455A1

  公开（公告）日：2004-05-13

  Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

  本发明揭示了治疗、预防和/或管理黄斑变性的方法。具体实施方式包括单独或与第二种活性剂和/或手术联合使用免疫调节化合物或其药学上可接受的盐、溶剂化物、水合物、立体异构体、笼合物或前药的给药。还公开了适用于本发明方法的制药组合物、单剂量制剂和套件。